FDA Grants Approval for Sugammadex Sodium ANDA214306 by Zenara
The FDA has granted approval for the ANDA214306 application for Sugammadex Sodium submitted by Zenara.
Published: August 1, 2026
Updated: August 1, 2026
Author: Humanexa Intelligence
Therapeutic area: Anesthesia / Neuromuscular Blockade
Asset: Zenara
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
Zenara
Indication
Signal assessment
Signal strength
high
Confidence level
high
Signalhigh
Confidencehigh
Why it matters
The FDA's approval of Zenara's Sugammadex Sodium marks a significant entry into the neuromuscular blockade market, intensifying competition. Pharma strategy teams must evaluate the implications for pricing and market share of existing products in this therapeutic area.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market entry timelines and any subsequent pricing strategies from Zenara and competitors.
Related companies & assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.